Aratana Therapeutics Inc (PETX)

9.07
0.03 0.33
NASDAQ : Health Care
Prev Close 9.04
Open 9.09
Day Low/High 8.90 / 9.19
52 Wk Low/High 2.56 / 19.99
Volume 602.89K
Avg Volume 679.20K
Exchange NASDAQ
Shares Outstanding 35.42M
Market Cap 321.22M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Little Stocks With Big Upside

3 Little Stocks With Big Upside

Some small caps I own are on the move of late, and are still attractive.

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Local Post-Operative Analgesia to Provide Extended Pain Control

It May Be Dull, but That's No Reason to Be Negative

It May Be Dull, but That's No Reason to Be Negative

Bears continue to have a tough time gaining traction.

Think Big on These Small Biotechs

Think Big on These Small Biotechs

New drugs give small-cap companies opportunity to expand markets and revenues.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Buyers Are Finding Support Despite Negative Breadth

Buyers Are Finding Support Despite Negative Breadth

There is still some good speculative action out there.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Aratana Therapeutics Files For FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Aratana Therapeutics Files For FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Local Post-Operative Analgesia Provides Extended Pain Control

4 Stocks With Strong Technicals That You Should Watch

4 Stocks With Strong Technicals That You Should Watch

Here are four stocks with good technical strength pointing to higher prices.

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a strong on high relative volume candidate

Aratana Therapeutics Receives CMC Technical Section Complete Letter For Post-Operative Pain Therapeutic

Aratana Therapeutics Receives CMC Technical Section Complete Letter For Post-Operative Pain Therapeutic

Final Major Technical Section Complete Letter for NOCITA® (bupivacaine liposome injectable suspension)

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

Aratana Therapeutics Granted FDA Approval Of ENTYCE® (capromorelin Oral Solution)

Aratana Therapeutics Granted FDA Approval Of ENTYCE® (capromorelin Oral Solution)

First-of-its-Kind Ghrelin Mimetic

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a strong on high relative volume candidate

2 Small-Cap Stocks That Could Win Big

Investing in small-cap names take a lot of research and patience, but they can also be very rewarding.

Aratana Therapeutics To Discuss Global Strategic Collaboration With Elanco Animal Health

Aratana Therapeutics To Discuss Global Strategic Collaboration With Elanco Animal Health

Conference Call Today at 6:00 p.m. ET

Aratana, Elanco Announce Global Strategic Collaboration

Aratana, Elanco Announce Global Strategic Collaboration

Agreement to expand Elanco's companion animal portfolio, extend global reach of GALLIPRANT® (grapiprant tablets) in canine osteoarthritis therapy

Aratana Therapeutics (PETX) Stock: Weak On High Volume Today

Aratana Therapeutics (PETX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a weak on high relative volume candidate

Aratana Therapeutics (PETX) Is Today's Strong On High Volume Stock

Aratana Therapeutics (PETX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a strong on high relative volume candidate

Aratana Therapeutics (PETX) Stock Jumps Ahead of Drug Data Presentation

Aratana Therapeutics (PETX) Stock Jumps Ahead of Drug Data Presentation

Aratana Therapeutics (PETX) stock is spiking on Thursday afternoon as the pet therapeutics company said it will present pivotal efficacy and safety data about its galliprant tablets for dogs.

Aratana Therapeutics To Present GALLIPRANT® (grapiprant Tablets) Pivotal Data

Aratana Therapeutics To Present GALLIPRANT® (grapiprant Tablets) Pivotal Data

AAHA Session to Highlight Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs